A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT01633970. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Bevacizumab and/or Chemotherapy in Patients With Advanced Solid Tumors
Study identification
- NCT ID
- NCT01633970
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Genentech, Inc.
- Industry
- Enrollment
- 240 participants
Conditions and interventions
Conditions
Interventions
- 5-FU Drug
- Atezolizumab Drug
- Bevacizumab Drug
- Carboplatin Drug
- Leucovorin Drug
- Nab-paclitaxel Drug
- Oxaliplatin Drug
- Paclitaxel Drug
- Pemetrexed Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 10, 2012
- Primary completion
- Feb 25, 2020
- Completion
- Feb 25, 2020
- Last update posted
- Oct 7, 2020
2012 – 2020
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Yale University | New Haven | Connecticut | 06511 | — |
| Georgetown University Medical Center Lombardi Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| Uni of Chicago | Chicago | Illinois | 60637 | — |
| Massachusetts General Hospital. | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Med Ctr | Boston | Massachusetts | 02215 | — |
| Dana Farber Can Ins | Boston | Massachusetts | 02215 | — |
| Laura and ISAAC Perlmutter Cancer Center at NYU Langone. | New York | New York | 10016 | — |
| Duke University Medical Center | Durham | North Carolina | 27705 | — |
| Carolina BioOncology Institute; Can Therapy & Res Ctr | Huntersville | North Carolina | 28078 | — |
| Sarah Cannon Research Inst. | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01633970, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 7, 2020 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01633970 live on ClinicalTrials.gov.